Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Loss of PRDM11 promotes MYC-driven lymphomagenesis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Low vs. high hemoglobin trigger for Transfusion in Vascular surgery (TV): a randomized clinical feasibility trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The preleukemic TCF3-PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. Yet another susceptibility variant for ALL: what's next?

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  5. A small change makes a big difference in Hodgkin lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Epigenetic therapy in hematological cancers

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

The PR-domain (PRDM) family of genes encodes transcriptional regulators, several of which are deregulated in cancer. By using a functional screening approach, we sought to identify novel tumor suppressors among the PRDMs. Here we demonstrate oncogenic collaboration between depletion of the previously uncharacterized PR-domain family member Prdm11 and overexpression of MYC. Overexpression of PRDM11 inhibits proliferation and induces apoptosis. Prdm11 knockout mice are viable, and loss of Prdm11 accelerates MYC-driven lymphomagenesis in the Eµ-Myc mouse model. Moreover, we show that patients with PRDM11-deficient diffuse large B-cell lymphomas (DLBCLs) have poorer overall survival and belong to the nongerminal center B-cell-like subtype. Mechanistically, genome-wide mapping of PRDM11 binding sites coupled with transcriptome sequencing in human DLBCL cells evidenced that PRDM11 associates with transcriptional start sites of target genes and regulates important oncogenes such as FOS and JUN. Hence, we characterize PRDM11 as a putative novel tumor suppressor that controls the expression of key oncogenes, and we add new mechanistic insight into B-cell lymphomagenesis.

Udgave nummer8
Sider (fra-til)1272-81
Antal sider10
StatusUdgivet - 19 feb. 2015

ID: 45690474